Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accumulated Expenses (2018 - 2024)

Zevra Therapeutics' Accumulated Expenses history spans 9 years, with the latest figure at $6.1 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses fell 42.59% year-over-year to $6.1 million; the TTM value through Dec 2024 reached $6.1 million, down 42.59%, while the annual FY2024 figure was $6.1 million, 42.59% down from the prior year.
  • Accumulated Expenses reached $6.1 million in Q4 2024 per ZVRA's latest filing, down from $10.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.7 million in Q4 2023 to a low of $700000.0 in Q4 2021.
  • Average Accumulated Expenses over 5 years is $4.1 million, with a median of $1.7 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: tumbled 46.11% in 2021, then soared 537.84% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $1.3 million in 2020, then crashed by 46.11% to $700000.0 in 2021, then surged by 139.0% to $1.7 million in 2022, then skyrocketed by 537.84% to $10.7 million in 2023, then tumbled by 42.59% to $6.1 million in 2024.
  • Per Business Quant, the three most recent readings for ZVRA's Accumulated Expenses are $6.1 million (Q4 2024), $10.7 million (Q4 2023), and $1.7 million (Q4 2022).